Skip to main
AMPH

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. has demonstrated notable sales momentum, particularly with Baqsimi, which experienced approximately a 20% quarter-over-quarter increase in prescriptions during the third quarter of 2025, aided by collaboration with MNKD and seasonal trends. The company anticipates maintaining a flat year-over-year top line in 2025, followed by a projected return to double-digit growth in 2026, underpinned by expectations of high-single digit unit growth for its products. Additionally, the strong performance of Primatene Mist in the third quarter positions the company to benefit from seasonal demand, contributing positively to its overall financial outlook.

Bears say

Amphastar Pharmaceuticals Inc. is facing significant challenges in its product portfolio, particularly with iron sucrose and glucagon, which are expected to generate much lower sales than previously anticipated, with projections of under $70 million for glucagon starting in 2026. Increased competition in the market has impacted the sales estimates for these products significantly, with iron sucrose's sales now forecasted around $5 million per quarter and glucagon sales anticipated to trend down further. The company's outlook for growth has been moderated from double-digit expectations to a range of high-single to low-double digits due to pressures from a competitive landscape and pipeline limitations.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.